News brief­ing: ADC gets a speedy FDA re­view for their DL­B­CL ther­a­py; Qi­a­gen teams with the world's new fa­vorite biotech

The transat­lantic biotech ADC Ther­a­peu­tics is get­ting a speedy re­view for its an­ti-body drug con­ju­gate lon­cas­tux­imab tesirine (Lon­ca), de­vel­oped for re­lapsed or re­frac­to­ry dif­fuse large B-cell lym­phoma.

ADC $AD­CT said Fri­day morn­ing that the FDA put their drug on the fast lane, pro­vid­ing a pri­or­i­ty re­view for the drug with a May 21 PDU­FA date. The biotech won over reg­u­la­tors with Phase II da­ta that re­flect­ed an over­all re­sponse rate of 48.3% (70/145 pa­tients) and a com­plete re­sponse rate of 24.1%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER